Fig. 2.

D3T treatment exacerbates AGE-induced damage. (A) D3T exacerbates AGE-induced viability loss. Differentiated cells were treated with 100 µM D3T for 24 h prior to 5 mg/mL BSA or AGE treatment. D3T was replenished during BSA and AGE treatment. Viability was assessed using an MTT assay and results are presented as values relative to control (BSA) group. (B) D3T exacerbates AGE-induced oxidative stress. Differentiated cells were treated with 100 µM D3T for 24 h prior to 5 mg/mL BSA or AGE treatment. D3T was replenished during BSA and AGE treatment. Data were analyzed by one-way ANOVA with Tukey's post-hoc analysis from 4 to 5 independent experiments. Bars with superscript letters different from each other are significantly different (p < 0.05). (C) D3T treatment results in increased G6PD protein expression. Differentiated cells were treated with 100 µM D3T for 24 h prior to 5 mg/mL BSA or AGE treatment. D3T was replenished during BSA and AGE treatment. Blots shown are representative samples of each group. G6PD and β-actin bands appear at approximately 60 kDa and 45 kDa molecular weights, respectively. Data were analyzed by one-way ANOVA with Tukey's post-hoc analysis from 3 independent experiments. Bars not linked by a superscript letter are significantly different from each other (p < 0.05).